Weight Watchers and Dear Media launch The Weigh In, a weekly GLP-1 podcast
Weight Watchers' first GLP-1-focused podcast, co-produced with Dear Media, starts September 16 and pairs user stories with expert guests, though the company also sells weight-management programs and medication access.
Weight Watchers and the podcast network Dear Media announced on September 9, 2026 that they are launching "The Weigh In," a weekly podcast about GLP-1 medications [1]. The announcement describes it as Weight Watchers' first podcast about GLP-1s [1]. The show is hosted by Samhita Mukhopadhyay, former executive editor of Teen Vogue and now head of content and impact at Weight Watchers [1].
New full-length video episodes are scheduled for release every Wednesday on YouTube, with audio versions on major podcast platforms. The show becomes available September 16 [1].
Season one is set to feature what the announcement calls real GLP-1 users and experts, including The Cut editor-in-chief Lindsay Peoples, fashion stylist Erin Walsh and Weight Watchers' own Julie Rice [1]. Each episode is billed as breaking down "the cultural questions surrounding GLP-1s: the science, the relationships, the body politics, the identity shifts, and everything in between" [1].
Mukhopadhyay said she started taking a GLP-1 when she "needed to make an intervention in my own health" and could not find anyone talking honestly about "shame, identity, and how to take care of yourself without drowning in self-hate" [1]. "The Weigh In is the show I wish had existed when I started," she said [1]. The announcement says she has written about taking a GLP-1 after losing her father to diabetes-related complications [1].
Mark Mullett, Dear Media's president of global entertainment, said the network wants "unfiltered storytelling" about the cultural impact of GLP-1s, adding that the show goes "beyond the headlines" [1]. Julie Rice, Weight Watchers' chief experience officer, said community "has always been at the heart of our impact" and that the podcast carries that legacy "into the GLP-1 era" [1]. Glossy reported the launch and said it interviewed Mukhopadhyay and Mullett about the show [2].
Weight Watchers describes itself as offering an "integrated support system built for the GLP-1 era" that includes clinical interventions and access to GLP-1 medications "when clinically appropriate" [1]. The company says it has operated since 1963 and calls itself the most studied commercial weight management program [1]. Dear Media says it hosts 100 top-rated entertainment, pop culture and lifestyle shows [1].
Why it matters for patients
Millions of adults are deciding whether to start a GLP-1 or are already taking one, and this is a branded, corporate-backed entry into that conversation rather than a clinical or government source. Glossy framed the launch as an effort "to crush GLP-1 stigma" [2]; the announcement itself frames it as creating space for candid talk about bodies, identity and relationships during treatment [1].
Listeners should note who is talking. The host is a Weight Watchers executive who says she takes a GLP-1 [1], and the company that produces the show also sells weight-management programs and access to GLP-1 medications when clinically appropriate [1]. That does not make the experiences shared on the show untrue, but it is a commercial context worth keeping in mind.
Several practical questions are not addressed in the announcement. It does not say whether licensed prescribers will appear to discuss side effects, dose changes or how patients get medication, whether episodes are reviewed by outside clinicians, how many episodes season one contains, or whether guests are paid. None of that has been reported [1][2]. The show is not described as medical advice, and it does not replace care from a prescriber or pharmacist.
The GLP-1 drugs discussed under this umbrella include semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound. The announcement does not name specific products [1].
What happens next
Images from the sources
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.